Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 402Triple Negative Breast Neoplasms 64Neoplasm Metastasis 50Neoplasms 19Breast Neoplasms, Male 14Colorectal Neoplasms 13Brain Neoplasms 13Stomach Neoplasms 11Pancreatic Neoplasms 11Colonic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Inflammatory Breast Neoplasms 6HER2-positive Breast Cancer 6Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Advanced Breast Cancer 5Rectal Neoplasms 4HER2 Positive Metastatic Breast Cancer 4Breast Cancer Metastatic 4Sarcoma 3Prostatic Neoplasms 3Meningeal Neoplasms 3Lymphoma, Non-Hodgkin 3Gallbladder Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Unknown Primary 2

Interventions

Loperamide 3Probiotics 1Octreotide 1Lapatinib 1Fecal Microbiota Transplantation 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diarrhea × Capecitabine × Breast × Clear all
NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Novartis

Phase 2 Terminated
62 enrolled 25 charts
Breast

Breast Neoplasms, Diarrhea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡